Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| P21 (Cerebrolysin Analog) | PT-141 (Bremelanotide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection. | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. |
| Timing | Morning dosing preferred for cognitive effects. | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. |
| Cycle Duration | 4-8 week cycles with 4-week rest periods. | As-needed basis. Not intended for daily use. |
| Evidence Level | animal_plus_anecdotal | strong_human |
P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.
Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
Morning dosing preferred for cognitive effects.
4-8 week cycles with 4-week rest periods.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →